Wang Xiaodong 4
4 · BeOne Medicines Ltd. · Filed Jun 15, 2026
Research Summary
AI-generated summary of this filing
BeOne Medicines (ONC) Director Wang Xiaodong Receives RSU Award
What Happened
Wang Xiaodong, a director and chair of the Scientific Advisory Board at BeOne Medicines (ONC), received two grants on June 11, 2026: 99,892 shares and 193,492 shares reported as awards (code A), totaling 293,384 restricted share units (RSUs). Both grants show a $0 transaction price because these are equity awards (not open-market purchases or sales). These awards are reported as including derivative securities (RSUs representing underlying ordinary shares).
Key Details
- Transaction date: 2026-06-11; Form 4 filed: 2026-06-15 (filed within the 2-business-day window).
- Grants: 99,892 shares (award) and 193,492 shares (award/derivative) — total 293,384 RSUs; reported price $0.
- Vesting: Footnotes indicate multi-year vesting over four years — 25% on the first anniversary of June 11, 2026, with remaining shares vesting either annually or in 36 monthly installments thereafter, subject to continued service; unvested securities may accelerate on certain termination events (see F1, F6).
- Ownership after transaction: the filing does not state total post-grant beneficial ownership for these awards.
- Other footnotes: certain holdings are held in family trusts or entities for which the reporting person disclaims beneficial ownership (F2–F4). F5 notes each ADS equals 13 ordinary shares (informational).
Context
These are grant awards (not purchases or sales) and are commonly used for compensation and retention. RSU grants report $0 as the acquisition price at grant; value to the insider will be realized as shares vest (and may be taxable at vesting). The filing appears timely and contains standard vesting and ownership-disclaimer footnotes; it does not indicate any immediate sale or cashless exercise associated with these awards.
Insider Transaction Report
- Award
Ordinary Shares
[F1]2026-06-11+99,892→ 4,682,493 total - Award
Share Option (Right to Buy)
[F5][F6]2026-06-11+193,492→ 193,492 totalExercise: $20.81Exp: 2036-06-10→ Ordinary Shares (193,492 underlying)
- 1,025,063(indirect: See Footnote)
Ordinary Shares
[F2] - 3,953,100(indirect: See Footnote)
Ordinary Shares
[F3] - 50(indirect: See Footnote)
Ordinary Shares
[F4]
Footnotes (6)
- [F1]Represents securities underlying restricted share units. 1/4th of the securities will vest on each anniversary of June 11, 2026, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.
- [F2]These securities are held by a family trust, the beneficiaries of which are the Reporting Person's family members, for which the Reporting Person disclaims beneficial ownership.
- [F3]These securities are held by Wang Investment LLC, of which 99% of the limited liability company interest is owned by two grantor retained annuity trusts, of which the Reporting Person's wife is a trustee, for which the Reporting Person disclaims beneficial ownership.
- [F4]These securities are held by the spouse of the Reporting Person.
- [F5]The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares.
- [F6]These securities vest over a four-year period as follows: 25% on the first anniversary of June 11, 2026 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.